<DOC>
	<DOCNO>NCT02154087</DOCNO>
	<brief_summary>Assess influence HP802-247 biochemical cellular marker inflammation chronic venous leg ulcer</brief_summary>
	<brief_title>A Phase 2 Exploratory Pharmacodynamic Study HP802-247 Venous Leg Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Leg Ulcer</mesh_term>
	<mesh_term>Varicose Ulcer</mesh_term>
	<criteria>Provide inform consent Age ≥ 18 year either sex Willing comply protocol instruction , include allow study assessment Have venous leg ulcer ( VLU ) knee ankle ( malleolus ) , surface area ≥ 4.0 cm x cm ≤ 15.0 cm x cm Venous insufficiency confirm duplex Doppler ultrasound examination valvular venous incompetence Arterial supply adequacy confirm Target ulcer involve full thickness skin loss , WITHOUT exposure tendon , muscle , bone Target ulcer duration ≥ 12 week ≤ 104 week ( 24 month ) . Acceptable state health nutrition History anaphylaxis , serum sickness , erythema multiforme reaction aprotinin , bovine serum albumin bovine serum protein , penicillin , streptomycin , amphotericin B component HP802247 , know sensitivity Iodine Prior diagnosis Systemic Lupus Erythematosus elevate antiDNA antibody titer , Buerger 's disease ( thromboangiitis obliterans ) , current diagnosis vasculitis , current diagnosis claudication Therapy another investigational agent within thirty ( 30 ) day Screening , study , participation previous HP802247 trial A target ulcer nonvenous etiology ( e.g. , sickle cell anemia , necrobiosis lipoidica diabeticorum , pyoderma gangrenosum , vasculopathic vasculitic ) Documented history osteomyelitis target wound location within 6 month precede Screening Visit Refusal inability tolerate compression therapy Therapy target ulcer Collagenase Santyl® ointment , autologous skin graft , biological dressing live cell product ( e.g. , Oasis® , Apligraf™ , Dermagraft™ ) within 30 day precede Screening Visit Therapy target ulcer topical growth factor within 1 week precede Screening Visit Current therapy systemic antibiotic Current systemic therapy cytotoxic drug Current therapy chronic ( &gt; 10 day ) oral corticosteroid Current therapy TNFα inhibitor History cancer precede 5 year ( carcinoma situ cervix adequately treat nonmelanoma skin cancer )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Venous leg ulcer</keyword>
	<keyword>Ulcer</keyword>
	<keyword>Venous stasis</keyword>
	<keyword>Compression</keyword>
</DOC>